Loading
Zymeworks Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to identifying, advancing, and bringing to market biological therapies aimed at combating cancer. Its pipeline features two primary experimental treatments: zanidatamab, a cutting-edge bispecific antibody currently undergoing Phase 1 and Phase 2 studies for various malignancies such as those affecting the biliary tract, gastroesophageal region (adenocarcinomas), breast, and colon; and ZW49, an antibody-drug conjugate targeting two sites on the human epidermal growth factor receptor 2 (HER2), which is in Phase 1 trials for advanced or spreading tumors that express HER2. Zymeworks maintains significant alliances with several pharmaceutical leaders, including Merck Sharp & Dohme Research Ltd., Eli Lilly and Company, Bristol-Myers Squibb company, GlaxoSmithKline Intellectual Property Development Ltd., Daiichi Sankyo Co., Ltd., Janssen Biotech, Inc., BeiGene, Ltd., and Exelixis, Inc. Furthermore, it engages in cooperative research and licensing agreements with LEO Pharma A/S, specifically for the exploration, advancement, and market introduction of bispecific antibodies, and with Iconic Therapeutics, Inc. Established in 2003, Zymeworks Inc. operates from its headquarters located in Vancouver, Canada.
Previous close
$25.26
−$1.27 · -4.79%
After-hours
$25.26
$0.00 · 0.00%
Oct 8, 7:30 PM ET
Regular session · ET · Market data may be delayed.
Zymeworks Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to identifying, advancing, and bringing to market biological therapies aimed at combating cancer. Its pipeline features two primary experimental treatments: zanidatamab, a cutting-edge bispecific antibody currently undergoing Phase 1 and Phase 2 studies for various malignancies such as those affecting the biliary tract, gastroesophageal region (adenocarcinomas), breast, and colon; and ZW49, an antibody-drug conjugate targeting two sites on the human epidermal growth factor receptor 2 (HER2), which is in Phase 1 trials for advanced or spreading tumors that express HER2. Zymeworks maintains significant alliances with several pharmaceutical leaders, including Merck Sharp & Dohme Research Ltd., Eli Lilly and Company, Bristol-Myers Squibb company, GlaxoSmithKline Intellectual Property Development Ltd., Daiichi Sankyo Co., Ltd., Janssen Biotech, Inc., BeiGene, Ltd., and Exelixis, Inc. Furthermore, it engages in cooperative research and licensing agreements with LEO Pharma A/S, specifically for the exploration, advancement, and market introduction of bispecific antibodies, and with Iconic Therapeutics, Inc. Established in 2003, Zymeworks Inc. operates from its headquarters located in Vancouver, Canada.
Day range
Current $25.26
52-week range
Current $25.26
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
2
Overpriced
Sentiment
62
Bullish
Risk
42
Elevated Risk
Momentum
53
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Zymeworks Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to identifying, advancing, and bringing to market biological therapies aimed at combating cancer. Its pipeline features two primary experimental treatments: zanidatamab, a cutting-edge bispecific antibody currently undergoing Phase 1 and Phase 2 studies for various malignancies such as those affecting the biliary tract, gastroesophageal region (adenocarcinomas), breast, and colon; and ZW49, an antibody-drug conjugate targeting two sites on the human epidermal growth factor receptor 2 (HER2), which is in Phase 1 trials for advanced or spreading tumors that express HER2. Zymeworks maintains significant alliances with several pharmaceutical leaders, including Merck Sharp & Dohme Research Ltd., Eli Lilly and Company, Bristol-Myers Squibb company, GlaxoSmithKline Intellectual Property Development Ltd., Daiichi Sankyo Co., Ltd., Janssen Biotech, Inc., BeiGene, Ltd., and Exelixis, Inc. Furthermore, it engages in cooperative research and licensing agreements with LEO Pharma A/S, specifically for the exploration, advancement, and market introduction of bispecific antibodies, and with Iconic Therapeutics, Inc. Established in 2003, Zymeworks Inc. operates from its headquarters located in Vancouver, Canada.
Day range
Current $25.26
52-week range
Current $25.26
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 105.97M USD | 76.3M USD | 76.01M USD | 412.48M USD | 26.68M USD |
| Cost of goods sold | — | — | 142.99M USD | — | — |
| Gross profit | 105.97M USD | 76.3M USD | −66.98M USD | 412.48M USD | 26.68M USD |
| Research and development | 137M USD | 134.62M USD | 143.62M USD | 208.6M USD | 199.75M USD |
| Selling, general, and administrative | 61.5M USD | 61.5M USD | 70.4M USD | 73.4M USD | 42.6M USD |
| Operating expenses | 198.5M USD | 213.41M USD | 71.08M USD | 281.95M USD | 242.31M USD |
| Interest income | 13.35M USD | 19.94M USD | 19.71M USD | 3.6M USD | 1.97M USD |
| Depreciation and amortization | 11.11M USD | 11.19M USD | 17.31M USD | 12M USD | 9.58M USD |
| Operating income | −92.54M USD | −137.11M USD | −138.05M USD | 130.53M USD | −215.63M USD |
| Net income | −81.13M USD | −122.7M USD | −118.67M USD | 124.34M USD | −211.84M USD |
Company facts updated Oct 9, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI44.37M0.00%2.3T USD0.03%$379.56-0.39%
iShares Russell 2000 ETFIWM31.91M0.04%77.7B USD0.19%$277.57-0.05%
iShares Biotechnology ETFIBB13.84M0.13%10.41B USD0.44%$200.48-1.41%
iShares Russell 2000 Growth ETFIWO11.3M0.08%14.04B USD0.24%$353.47-0.53%
Dimensional - US Small Cap ETFDFAS8.38M0.02%33.66B USD0.31%$78.10+0.23%
Vanguard Russell 2000 ETFVTWO7.96M0.04%18B USD0.06%$112.1-0.10%
Vanguard Health Care ETFVHT3.61M0.02%22B USD0.09%$313.85-0.46%
U.S. Micro Cap Portfolio ETFDFMC2.87M0.04%7.52B USD0.43%$57.70+0.35%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMiShares Biotechnology ETFIBBiShares Russell 2000 Growth ETFIWODimensional - US Small Cap ETFDFASVanguard Russell 2000 ETFVTWOVanguard Health Care ETFVHTU.S. Micro Cap Portfolio ETFDFMCAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
